MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Amgen Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

306.57 -1.53

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

304.93

Max

312.17

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.2B

627M

Pardavimai

586M

9.1B

P/E

Sektoriaus vid.

41.156

63.778

Pelnas, tenkantis vienai akcijai

5.31

Dividendų pajamingumas

3.06

Pelno marža

6.901

Darbuotojai

28,000

EBITDA

-517M

2.9B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+6.7% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.06%

2.39%

Kitas uždarbis

2025-05-01

Kitas dividendų mokėjimo data

2025-06-06

Kita Ex Dividend data

2025-05-16

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

14B

167B

Ankstesnė atidarymo kaina

308.1

Ankstesnė uždarymo kaina

306.57

Naujienos nuotaikos

By Acuity

52%

48%

302 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Amgen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-04 21:29; UTC

Uždarbis

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

2024-10-30 20:18; UTC

Uždarbis

Amgen Posts Higher 3Q Sales on Strong Demand

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-04 21:02; UTC

Uždarbis

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q Adj EPS $5.31 >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q Rev $9.1B >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q EPS $1.16 >AMGN

2025-02-04 21:01; UTC

Uždarbis

Amgen 4Q Net $627M >AMGN

2025-01-28 10:30; UTC

Svarbiausios naujienos

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

2024-12-27 07:00; UTC

Uždarbis

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

2024-12-23 15:04; UTC

Svarbiausios naujienos

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

2024-12-13 14:53; UTC

Svarbiausios naujienos

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

2024-11-30 12:00; UTC

Svarbiausios naujienos

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

2024-11-26 12:34; UTC

Svarbiausios naujienos

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

2024-11-04 12:00; UTC

Svarbiausios naujienos

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

2024-10-30 20:02; UTC

Uždarbis

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

2024-10-30 20:02; UTC

Uždarbis

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

2024-10-30 20:02; UTC

Uždarbis

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

2024-10-30 20:02; UTC

Uždarbis

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

2024-10-30 20:02; UTC

Uždarbis

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

2024-10-30 20:01; UTC

Uždarbis

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

2024-10-30 20:01; UTC

Uždarbis

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

2024-10-30 20:01; UTC

Uždarbis

Amgen 3Q Worldwide Neulasta Sales $110M >AMGN

Akcijų palyginimas

Kainos pokytis

Amgen Inc Prognozė

Kainos tikslas

By TipRanks

6.7% į viršų

12 mėnesių prognozė

Vidutinis 332.43 USD  6.7%

Aukščiausias 389 USD

Žemiausias 280 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Amgen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

18 ratings

11

Pirkti

6

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

304.35 / 318.66Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

302 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.